Effects of Prescription Omega-3-Acid Ethyl Esters on Non—High-Density Lipoprotein Cholesterol When Coadministered With Escalating Doses of Atorvastatin

Abstract

Objective: To evaluate the effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol (HDL-C) levels in atorvastatin-treated patients with elevated non-HDL-C and triglyceride levels. Results: Prescription omega-3-acid ethyl esters plus atorvastatin, 10, 20, and 40 mg/d, reduced median non-HDL-C levels by 40.2% vs 33.7% (P<.001), 46.9% vs 39.0% (P<.001), and 50.4% vs 46.3% (P<.001) compared with placebo plus the same doses of atorvastatin at the end of 8, 12, and 16 weeks, respectively. Prescription omega-3-acid ethyl esters plus atorvastatin also reduced median total cholesterol, triglyceride, and very low-density lipoprotein cholesterol levels and increased HDL-C levels to a significantly greater extent than placebo plus atorvastatin. Percent changes from baseline low-density lipoprotein-cholesterol, apolipoprotein A-I, and apolipoprotein B levels were not significantly different between groups at the end of the study.cOnclusiOn: Prescription omega-3-acid ethyl esters plus atorvastatin produced significant improvements in non-HDL-C and other lipid parameters in patients with elevated non-HDL-C and triglyceride levels.Mayo Clin Proc. 2010;85(2):122-128 ANOVA = analysis of variance; apo = apolipoprotein; CHD = coronary heart disease; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; P-OM3 = prescription omega-3-acid ethyl esters; TC = total cholesterol; VLDL = very low-density lipoprotein; VLDL-C = VLDL-cholesterol

Naturopathic medicine for the prevention of cardiovascular disease: a randomized clinical trial

“…5,12 Dietary recommendations were based on components of the Mediterranean and Portfolio dietary regimes. 13,14 Examples of prescriptions for natural health products included omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid, 12,15 The Framingham algorithm is a tool designed to estimate an individual's level of cardiovascular disease risk. The algorithm predicts the 10-year risk of a cardiovascular event based on a comp osite score of risk factors, including age, HDL, total cholesterol, systolic blood pressure, smoking status and diabetes status.…”

Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk

“…91,92 However, the effects of P-OM3s on Apo B levels are small. [93][94][95] Benefits of P-OM3 treatment on cardiovascular morbidity and mortality might be ascribed largely to nonlipid benefits.…”

Omega-3 Fatty Acids for Cardiovascular Disease Prevention

“…Two recent studies evaluated the impact of omega-3 supplementation in patients with residual hypertriglyceridemia (200-400 mg/dL) on statin therapy. In both these studies, 4 g/d of prescription omega-3 reduced elevated triglycerides and non-HDL-C significantly more than either simvastatin or atorvastatin alone [56,57]. Although prescription omega-3 is a useful adjunct in patients on statin therapy who have increased "residual risk" due to elevated triglycerides and non-HDL-C, no clinical trial data are available on the impact of reducing triglycerides with omega-3s with respect to CVD events.…”